Treatment of submassive pulmonary embolism with tenecteplase or placebo: Cardiopulmonary outcomes at 3 months: Multicenter double-blind, placebo-controlled randomized trial

215Citations
Citations of this article
323Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Summary: Background: Acute pulmonary embolism (PE) can worsen quality of life due to persistent dyspnea or exercise intolerance. Objective: Test if tenecteplase increases the probability of a favorable composite patient-oriented outcome after submassive PE. Methods: Normotensive patients with PE and right ventricular (RV) strain (by echocardiography or biomarkers) were enrolled from eight hospitals. All patients received low-molecular-weight heparin followed by random assignment to either a single weight-based bolus of tenecteplase or placebo, administered in a double-blinded fashion. The primary composite outcome included: (i) death, circulatory shock, intubation or major bleeding within 5 days or (ii) recurrent PE, poor functional capacity (RV dysfunction with either dyspnea at rest or exercise intolerance) or an SF36® Physical Component Summary (PCS) score < 30 at 90-day follow-up. Results: Eighty-three patients were randomized; 40 to tenecteplase and 43 to placebo. The trial was terminated prematurely. Within 5 days, adverse outcomes occurred in three placebo-treated patients (death in one and intubation in two) and one tenecteplase-treated patient (fatal intracranial hemorrhage). At 90 days, adverse outcomes occurred in 13 unique placebo-treated patients and five unique tenecteplase-treated patients Thus, 16 (37%) placebo-treated and six (15%) tenecteplase-treated patients had at least one adverse outcome (exact two-sided P = 0.017). Conclusions: Treatment of patients with submassive pulmonary embolism with tenecteplase was associated with increased probability of a favorable composite outcome. © 2014 International Society on Thrombosis and Haemostasis.

References Powered by Scopus

ATS statement: Guidelines for the six-minute walk test

9469Citations
N/AReaders
Get full text

The rand 36‐item health survey 1.0

2272Citations
N/AReaders
Get full text

Guidelines on the diagnosis and management of acute pulmonary embolism

2024Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report

4051Citations
N/AReaders
Get full text

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)

2998Citations
N/AReaders
Get full text

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

2482Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kline, J. A., Nordenholz, K. E., Courtney, D. M., Kabrhel, C., Jones, A. E., Rondina, M. T., … Hernandez, J. (2014). Treatment of submassive pulmonary embolism with tenecteplase or placebo: Cardiopulmonary outcomes at 3 months: Multicenter double-blind, placebo-controlled randomized trial. Journal of Thrombosis and Haemostasis, 12(4), 459–468. https://doi.org/10.1111/jth.12521

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 103

64%

Researcher 32

20%

Professor / Associate Prof. 20

12%

Lecturer / Post doc 6

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 173

85%

Nursing and Health Professions 18

9%

Pharmacology, Toxicology and Pharmaceut... 8

4%

Biochemistry, Genetics and Molecular Bi... 4

2%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free